Risuteganib for the treatment of DME

Peter Kaiser, MD, shares how risuteganib (Luminate, Allegro) can help with the treatment of DME when anti-VEGF treatment isn't a viable option. He presented his research  in Vancouver, British Columbia, during the 2018 annual meeting of the American Society of Retina Specialists.

Related Videos
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
Related Content
© 2023 MJH Life Sciences

All rights reserved.